NASDAQ · TNYA
Tenaya Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TNYA: Nov 9, 2026
Tenaya Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.09 | $-0.10 | 3 |
| Dec 2026 | $-0.09 | $-0.08 | $-0.10 | 3 |
| Mar 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · MarketBeat · Zacks · Fintel- RTTNews · Sep 14, 2:17 PM EDTBiotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains(RTTNews) – Several biotech stocks were in focus Monday, including Tyra Biosciences following a $400 million stock and warrant offering to advance its dabogratinib 3×3 strategy; Nasus Pharma after FDA clearance of its IND for intranasal epinephrine NS002; Bionano Genomics followi
- RTTNews · Sep 14, 10:37 AM EDTTenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up(RTTNews) – Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, on Monday announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401 for the treatment of PKP2-associated arrhythmogenic right ventricular cardio
- RTTNews · Sep 14, 8:43 AM EDTTenaya Therapeutics Announces RMAT Designation To TN-401(RTTNews) – Tenaya Therapeutics, Inc. (TNYA) announced the FDA has granted Regenerative Medicine Advanced Therapy designation to TN-401, Tenaya's gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Tenaya's RMAT applicatio
- MarketBeat · Aug 18, 4:01 AM EDTTenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion. Hyllengren
- RTTNews · Jun 30, 1:25 AM EDTTenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement(RTTNews) – Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026, following the planned retirement of Hiro Higa, Senior Vice President of Finance, in the third qu
- RTTNews · Jun 29, 10:09 AM EDTTenaya Therapeutics Appoints Eric Hyllengren As Chief Financial Officer(RTTNews) – Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, said on Monday that it has appointed Eric Hyllengren as Chief Financial Officer with effect from July 13.
- RTTNews · Jun 29, 8:56 AM EDTTenaya Therapeutics Appoints Eric Hyllengren As CFO(RTTNews) – Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, said on Monday that it has appointed Eric Hyllengren as Chief Financial Officer with effect from July 13.
- RTTNews · Jun 3, 9:47 AM EDTTenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM(RTTNews) – Tenaya Therapeutics, Inc. (TNYA) announced new interim data from its ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The results were presented today, showing consistent sign
- RTTNews · Jun 3, 4:39 AM EDTTenaya To Present Interim Data From MyPEAK-1 Trial In MYBPC3-Associated HCM Today; Stock Up(RTTNews) – Tenaya Therapeutics, Inc. (TNYA) announced that it will present new interim data today from Cohort 1 and Cohort 2 of the ongoing MyPEAK-1 Phase 1b/2 trial evaluating TN-201, its gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy. The webcast is
- RTTNews · May 7, 6:06 AM EDTTenaya Therapeutics Posts Narrower Q1 Loss, Highlights Progress Across Gene Therapy Pipeline(RTTNews) – Tenaya Therapeutics, Inc. (TNYA) reported its first-quarter 2026 financial results and provided a business update, noting continued progress across its gene therapy and small-molecule pipeline targeting genetic cardiomyopathies and related heart conditions.
- Zacks · May 6, 5:25 PM EDTTenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue EstimatesTenaya Therapeutics (TNYA) delivered earnings and revenue surprises of +4.26% and -97.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Mar 27, 3:14 PM EDTTenaya Therapeutics (TNYA) Price Target Increased by 11.11% to 10.20The average one-year price target for Tenaya Therapeutics (NasdaqGS:TNYA) has been revised to $10.20 / share. This is an increase of 11.11% from the prior estimate of $9.18 dated February 21, 2026. The price target is an average of many targets provided by ana
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tenaya Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.